Products Enteric-coated mycophenolate sodium
Enteric-coated mycophenolate sodium Phase 3 Completed 📈 Rising Prevention of Acute Rejection After Kidney Transplantation
Prevention of Acute Rejection After Kidney Transplantation
Mar 1, 2004 → Jun 1, 2005
About Enteric-coated mycophenolate sodium Enteric-coated mycophenolate sodium is a phase 3 stage product being developed by Novartis for Prevention of Acute Rejection After Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00171392. Target conditions include Prevention of Acute Rejection After Kidney Transplantation.
Clinical Trials (7) NCT ID Phase Status Start Completion Indication NCT01467011 Pre-clinical Completed Dec 1, 2010 Dec 1, 2013 End Stage Liver Disease NCT00351377 Phase 3 Completed Jun 1, 2006 Jun 1, 2009 Autoimmune Disease NCT00171379 Phase 3 Completed Mar 1, 2004 Jun 1, 2005 Prevention of Acute Rejection After Kidney Transplantation NCT00171392 Phase 3 Completed Mar 1, 2004 Jun 1, 2005 Prevention of Acute Rejection After Kidney Transplantation NCT00239057 Phase 3 Completed May 1, 2002 Jan 1, 2005 Maintenance Renal Transplantation NCT00239031 Phase 3 Completed Mar 1, 2002 Jul 1, 2005 Denovo Renal Transplantation NCT00574743 Approved Completed Jan 1, 2002 — Heart Transplantation
Competing Products 20 competing products in Prevention of Acute Rejection After Kidney Transplantation
See all competitors Product Company Stage Hype Score edoxaban + enoxaparin sodium Daiichi Sankyo Phase 3 Mifepristone Eli Lilly Phase 2 EXANTA AstraZeneca Phase 2 Risk of low dose aspirin discontinuation AstraZeneca Pre-clinical DAPA/MET XR + DAPA + MET XR AstraZeneca Phase 3 Esomeprazole + Placebo AstraZeneca Phase 3 PCV15 Merck Pre-clinical Raltegravir Merck Approved RotaTeq (V260) + IPV Merck Phase 3 V501 Merck Phase 3 Zostavax Merck Phase 3 V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920 Merck Phase 3 Letermovir + Placebo Merck Phase 3 Meningococcal C conjugate vaccine Novartis Approved Meningococcal C conjugate vaccine Novartis Approved rMenB+OMV NZ Novartis Phase 3 Enteric-Coated Mycophenolate Sodium Novartis Phase 3 Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml Novartis Phase 3 Meningococcal C Conjugate Vaccine Novartis Phase 3 MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation) + MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation) + MenACWY PS (MenACWY-CRM, polysaccharide vaccine) + HBV (Hepatitis B vaccine) + Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197) + MMR (Measles, Mumps and Rubella vaccine) + DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine) + Menjugate (Men C conjugated vaccine) Novartis Phase 2
Other Products from Novartis